Diana Hausman

Dr. Hausman was most recently Chief Medical Officer at Zentalis Pharmaceuticals where she had previously been a member of the Board of Directors. She currently serves as a member of the Board of Directors at Immuneering Corporation.

Prior to Zentalis, Dr.  Hausman was Chief Medical Officer at Link Immunotherapeutics and at Lengo Therapeutics (acquired by Blueprint Medicines Corporation). Dr. Hausman also served as Chief Medical Officer at Zymeworks Inc. and Oncothyreon Inc. (acquired by Seagen/Pfizer). She has previously held positions of increasing responsibility at Zymogenetics, Berlex and Immunex.

Dr. Hausman received an A.B. In biology from Princeton University, M.D. from the University of Pennsylvania, and internal medicine and specialty training in hematology and medical oncology at the University of Washington, Seattle.